MTOR and familial pancreatic carcinoma: Furthermore, analysis of the reverse phase protein array (RPPA) data in The Cancer Genome Atlas (TCGA) project25,26 points to a significant survival benefit in pancreatic cancer patients with high mTOR protein expression in their tumors (hazard ratio = 0.381, p = 0.022).